{"id":2308,"date":"2022-07-05T10:21:50","date_gmt":"2022-07-05T10:21:50","guid":{"rendered":"https:\/\/emergencydrug.com\/?post_type=product&#038;p=2308"},"modified":"2024-09-30T07:03:31","modified_gmt":"2024-09-30T07:03:31","slug":"prostaxen-apalutamide-60mg","status":"publish","type":"product","link":"https:\/\/emergencydrug.com\/ko-kr\/shop\/prostaxen-apalutamide-60mg\/","title":{"rendered":"Prostaxen (Apalutamide) 60 Mg &#8211; 30 Tablets"},"content":{"rendered":"<p>COMPOSITION PROSTAXEN : Each film coated tablet contains <a href=\"https:\/\/emergencydrug.com\/ko-kr\/mc_generic\/apalutamide\/\">Apalutamide INN<\/a> 60 mg.<\/p>\n<p>&nbsp;<\/p>\n<h2>INDICATION AND USAGE of Prostaxen<\/h2>\n<p><span style=\"font-weight: 400;\">Apalutamide is an androgen receptor inhibitor indicated for the <\/span><span style=\"font-weight: 400;\">treatment of patients with:\u00a0<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"> metastatic castration-sensitive prostate cancer\u00a0<\/span><\/li>\n<li><span style=\"font-weight: 400;\"> non-metastatic castration-resistant prostate cancer.\u00a0<\/span><\/li>\n<\/ul>\n<h3><b>PHARMACOLOGY:\u00a0<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Prostaxen is an orally administered, selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the <\/span><span style=\"font-weight: 400;\">AR<\/span><span style=\"font-weight: 400;\">. Apalutamide prevents AR nuclear translocation, inhibits DNA binding, im<\/span><span style=\"font-weight: 400;\">p<\/span><span style=\"font-weight: 400;\">edes AR-mediated <\/span><span style=\"font-weight: 400;\">t<\/span><span style=\"font-weight: 400;\">ranscription, and lacks androgen receptor agonist activity. Apalutamide treatment decreases tumor cell proliferation and increases apoptosis leading to potent antitumor activity.\u00a0<\/span><\/p>\n<h3><b>DOSAGE AND ADMINISTRATION:\u00a0<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The recommended dose of Apalutamide is 240 mg (four 60 mg <\/span><span style=\"font-weight: 400;\">tablets) administered orally once daily. Swallow the tablets whole. Apalutamide can be taken with or without food.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Patients should also receive a gonadotropin-releasing hormone <\/span><i><span style=\"font-weight: 400;\">(<\/span><\/i><span style=\"font-weight: 400;\">GnRH) analo<\/span><span style=\"font-weight: 400;\">g <\/span><span style=\"font-weight: 400;\">concurrently <\/span><span style=\"font-weight: 400;\">or sh<\/span><span style=\"font-weight: 400;\">ould <\/span><span style=\"font-weight: 400;\">have had <\/span><span style=\"font-weight: 400;\">a bilateral <\/span><span style=\"font-weight: 400;\">orchiectomy.\u00a0<\/span><\/p>\n<p><b>CONTRAINDICATION:<\/b><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Hypersensitivity to the active substance<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Women who are or may become pregnant<\/span><\/li>\n<\/ul>\n<h4><b>WARNINGS AND PRECAUTIONS:\u00a0<\/b><\/h4>\n<h5><b>\u00a0Seizure: <\/b><\/h5>\n<p><span style=\"font-weight: 400;\">Apalutamide is not recommended in patients <\/span><span style=\"font-weight: 400;\">w<\/span><span style=\"font-weight: 400;\">ith a history <\/span><span style=\"font-weight: 400;\">of <\/span><span style=\"font-weight: 400;\">seizures or other predisposing factors including, but not limited to<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">underlying brain injury, recent stroke (within one year), primary brain <\/span><span style=\"font-weight: 400;\">tumors or brain metastases<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">If a seizure develops during treatment <\/span><span style=\"font-weight: 400;\">with Apalutamide, treatment should be discontinued permanently.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In two randomized studies (SPARTAN and TITAN)<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">seizure occurre<\/span><span style=\"font-weight: 400;\">d <\/span><span style=\"font-weight: 400;\">in 0.4% of patients receiving apalutamide and in 0.2% of patients treated with placebo. These studies excluded patients with a history <\/span><span style=\"font-weight: 400;\">of seizure or predisposing factors for seizure.\u00a0<\/span><\/p>\n<h5><b>Falls and fractures:<\/b><\/h5>\n<p><b> <\/b><span style=\"font-weight: 400;\">Falls a<\/span><span style=\"font-weight: 400;\">nd f<\/span><span style=\"font-weight: 400;\">ractures occurred in patients receivin<\/span><span style=\"font-weight: 400;\">g a<\/span><span style=\"font-weight: 400;\">palutamide<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">Patients should be evaluated for fracture and fall risk before starting <\/span><span style=\"font-weight: 400;\">Apalutamide and should continue to be monitored and managed <\/span><span style=\"font-weight: 400;\">according to established treatment guidelines and use of bone-targeted agents should be considered. <\/span><\/p>\n<h5><b>Ischaemic heart disease: <\/b><\/h5>\n<p><span style=\"font-weight: 400;\">Ischaemic heart disease, including events leading to death, occurred <\/span><span style=\"font-weight: 400;\">in patients treated with Apalutamide. The majority of patients had cardiac risk factors<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">Patients should be monitored for signs and <\/span><span style=\"font-weight: 400;\">symptoms of ischaemic heart di<\/span><span style=\"font-weight: 400;\">s<\/span><span style=\"font-weight: 400;\">ease a<\/span><span style=\"font-weight: 400;\">nd <\/span><span style=\"font-weight: 400;\">management of cardiovascular <\/span><span style=\"font-weight: 400;\">r<\/span><span style=\"font-weight: 400;\">isk factors<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">such <\/span><span style=\"font-weight: 400;\">as <\/span><span style=\"font-weight: 400;\">hypertension<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">diabetes<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">or <\/span><span style=\"font-weight: 400;\">dyslipidaemia should be optimized as per standard of care.\u00a0<\/span><\/p>\n<h5><b>Concomitant use with other medicinal products:<\/b><\/h5>\n<p><span style=\"font-weight: 400;\">Apalutamide is a potent enzyme inducer and may lead to loss of <\/span><span style=\"font-weight: 400;\">efficacy of many commonly used medicinal products<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">Concomitant <\/span><span style=\"font-weight: 400;\">use of apalutamide <\/span><span style=\"font-weight: 400;\">wi<\/span><span style=\"font-weight: 400;\">th medicinal products that <\/span><span style=\"font-weight: 400;\">are sen<\/span><span style=\"font-weight: 400;\">sitive <\/span><span style=\"font-weight: 400;\">substrates of many metabolizing enzymes or transporters should <\/span><span style=\"font-weight: 400;\">generally be avoided if their therapeutic effect is of large importanc<\/span><span style=\"font-weight: 400;\">e <\/span><span style=\"font-weight: 400;\">to the patient<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">and if dose adjustments cannot easily be performed <\/span><span style=\"font-weight: 400;\">based on monitoring of efficacy or plasma concentrations.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Co<\/span><span style=\"font-weight: 400;\">&#8211;<\/span><span style=\"font-weight: 400;\">administration of apalutamide with warfarin and coumarin<\/span><span style=\"font-weight: 400;\">&#8211;<\/span><span style=\"font-weight: 400;\">like <\/span><span style=\"font-weight: 400;\">anticoagulants should be avoided<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">If Apalutamide is co-administered <\/span><span style=\"font-weight: 400;\">with an anticoagulant metabolized by CYP2C9 (such as warfarin or acenocoumarol)<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">additional International Normalized\u00a0Ratio (INR) monitoring should be conducted.\u00a0<\/span><\/p>\n<h5><b>Recent cardiovascular disease: <\/b><\/h5>\n<p><span style=\"font-weight: 400;\">Patients with clinically significant cardiovascular disease in the past 6 months includin<\/span><span style=\"font-weight: 400;\">g <\/span><span style=\"font-weight: 400;\">severe<\/span><i><span style=\"font-weight: 400;\">\/<\/span><\/i><span style=\"font-weight: 400;\">unstable angina, myocardial infarction<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">symptomatic congestive heart failure, arterial or venous thromboembolic events (e.<\/span><span style=\"font-weight: 400;\">g<\/span><span style=\"font-weight: 400;\">., pulmonary embolism, cerebrovascular accident <\/span><span style=\"font-weight: 400;\">including transient ischaemic attacks)<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">or clinically significan<\/span><span style=\"font-weight: 400;\">t <\/span><span style=\"font-weight: 400;\">ventricular arrhythmias <\/span><span style=\"font-weight: 400;\">w<\/span><span style=\"font-weight: 400;\">ere excluded from the clinical studies<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">Therefore<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">the safety of apalutamide in these patients has not bee<\/span><span style=\"font-weight: 400;\">n <\/span><span style=\"font-weight: 400;\">established<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">If Apalutamide is prescribed<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">patients with clinically <\/span><span style=\"font-weight: 400;\">significant cardiovascular dise<\/span><span style=\"font-weight: 400;\">as<\/span><span style=\"font-weight: 400;\">e should be monitore<\/span><span style=\"font-weight: 400;\">d for r<\/span><span style=\"font-weight: 400;\">isk <\/span><span style=\"font-weight: 400;\">factors su<\/span><span style=\"font-weight: 400;\">ch <\/span><span style=\"font-weight: 400;\">as hypercholesterolaemia<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">hypertriglyceridaemia<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">or other cardio-metabolic disorders. Patients should be treated after <\/span><span style=\"font-weight: 400;\">initiating Apalutamide for these conditions according to establishe<\/span><span style=\"font-weight: 400;\">d <\/span><span style=\"font-weight: 400;\">treatment guidelines.\u00a0<\/span><\/p>\n<h5><b>Androgen deprivation therapy may prolong the QT interval: <\/b><\/h5>\n<p><span style=\"font-weight: 400;\">In patients with a history of or risk factors for QT prolongation and in patients receivin<\/span><span style=\"font-weight: 400;\">g co<\/span><span style=\"font-weight: 400;\">ncomitant medicinal products t<\/span><span style=\"font-weight: 400;\">hat <\/span><span style=\"font-weight: 400;\">might <\/span><span style=\"font-weight: 400;\">prolong the QT interval, physicians should assess the benefit-risk <\/span><span style=\"font-weight: 400;\">ratio including the potential for Torsade de pointes prior to initiating <\/span><span style=\"font-weight: 400;\">Apalutamide.<\/span><\/p>\n<h2><b>Prostaxen SIDE EFFE<\/b><b>C<\/b><b>TS:<\/b><\/h2>\n<p><b> <\/b><span style=\"font-weight: 400;\">The following clinically significant adverse reactions are observed in <\/span><span style=\"font-weight: 400;\">clinical trial:\u00a0<\/span><\/p>\n<ul>\n<li><b> Endocrine disorders<\/b><span style=\"font-weight: 400;\">: Hypothyroidism <\/span><\/li>\n<li><b>Metabolism and nutrition disorders<\/b><span style=\"font-weight: 400;\">: hypercholesterolaemia<\/span><span style=\"font-weight: 400;\">, <\/span>hypertriglyceridaemia<\/li>\n<li><b>Nervous system disorders: <\/b><span style=\"font-weight: 400;\">Dysgeusia<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">seizure <\/span><\/li>\n<li><b>Cardiac disorders<\/b><span style=\"font-weight: 400;\">: ischemic heart disease <\/span><\/li>\n<li><b>Vascular disorders<\/b><span style=\"font-weight: 400;\">: hot flush<\/span><span style=\"font-weight: 400;\">, <\/span><span style=\"font-weight: 400;\">hypertension <\/span><\/li>\n<li><b>Gastrointestinal disorders<\/b><span style=\"font-weight: 400;\">: diarrhea <\/span><\/li>\n<li><b>Skin and subcutaneous tissue disorders: <\/b>skin rash, pruritus<\/li>\n<li><b>Musculoskeletal and connective tissue disorders<\/b><span style=\"font-weight: 400;\">: fracture<\/span><span style=\"font-weight: 400;\">, <\/span>arthralgia, muscle spasm<\/li>\n<li><b>General disorders and administration site conditions: <\/b><span style=\"font-weight: 400;\">fatigue <\/span><\/li>\n<li><b>Investigations<\/b><span style=\"font-weight: 400;\">: weight decreased <\/span><\/li>\n<li><strong>Injury,<\/strong>\u00a0<b>poisoning\u00a0and procedural complications<\/b>: fall, fracture<\/li>\n<\/ul>\n<h3><b>DRUG INTERACTIONS: <\/b><\/h3>\n<p><b>Effect of Other Drugs on Apalutamide: <\/b><span style=\"font-weight: 400;\">C<\/span><i><span style=\"font-weight: 400;\">Y<\/span><\/i><span style=\"font-weight: 400;\">P2C8 plays a role in the elimination of Apalutamide and in the formation of its active metabolite. In a drug-drug interaction study, the <\/span><span style=\"font-weight: 400;\">Cmax of Apalutamide d<\/span>ecreased <span style=\"font-weight: 400;\">by 21% while AUC inc<\/span>reased by <span style=\"font-weight: 400;\">68% following co-administration of Apalutamide 240 mg single dose with gemfibrozil (strong CYP2C8 inhibitor). For the active moieties (sum of apalutamide plus the potency adjusted active metabolite), <\/span>Cmax decreased b<span style=\"font-weight: 400;\">y 21% while AUC increased by 45%. No initial <\/span><span style=\"font-weight: 400;\">d<\/span><span style=\"font-weight: 400;\">ose adjustment is necessary when Apalutamide is co-administered <\/span><span style=\"font-weight: 400;\">with a strong inhibitor of CYP2C8 (<\/span><span style=\"font-weight: 400;\">e<\/span><span style=\"font-weight: 400;\">.g., ge<\/span><span style=\"font-weight: 400;\">m<\/span><span style=\"font-weight: 400;\">fibrozil, clopidogrel) <\/span><span style=\"font-weight: 400;\">howe<\/span><i><span style=\"font-weight: 400;\">v<\/span><\/i><span style=\"font-weight: 400;\">er, a reduction of the Apalutamide dose based on tolerability <\/span><span style=\"font-weight: 400;\">should be considered . Mild or moderate inhibitors of CYP2C8 are not <\/span>expe<span style=\"font-weight: 400;\">cted to affect the exposure of Apalutamide.\u00a0<\/span><\/p>\n<p><b>Medicinal products that Inhibit CYP<\/b><b>3<\/b><b>A<\/b><b>4: <\/b><span style=\"font-weight: 400;\">CYP3A4 plays a role in the elimination of Apalutamide and in the formation of its active metabolite. In a drug-drug interaction study, the <\/span><span style=\"font-weight: 400;\">Cmax of apalutamide decreased by 22% while AUC w<\/span><span style=\"font-weight: 400;\">a<\/span><span style=\"font-weight: 400;\">s similar <\/span><span style=\"font-weight: 400;\">following co-administration of Apalutamide as a 240 mg single dose <\/span><span style=\"font-weight: 400;\">with itraconazole (strong CYP3A4 inhibitor). For the active moieties <\/span><span style=\"font-weight: 400;\">(sum of apalutarnide plus the potency adjusted active metabolite), <\/span>Cmax decrease<span style=\"font-weight: 400;\">d by 22% while AUC was again similar. No initial dose <\/span><span style=\"font-weight: 400;\">adjustment is necessary when Apalutamide is co-administered with a <\/span><span style=\"font-weight: 400;\">strong inhibitor of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) how<\/span><i><span style=\"font-weight: 400;\">e<\/span><\/i><span style=\"font-weight: 400;\">ver, <\/span><span style=\"font-weight: 400;\">a <\/span><span style=\"font-weight: 400;\">reduction of the Apalutamide do<\/span>se based on <span style=\"font-weight: 400;\">tolerability should be co<\/span><span style=\"font-weight: 400;\">n<\/span><span style=\"font-weight: 400;\">sidered .Mild or moderate inhibitors of CYP3A4 are not expected to affect the exposure of Apalutamide.\u00a0<\/span><\/p>\n<p><b>Medicinal products that Induce CYP3A4 or CYP2C8: <\/b><span style=\"font-weight: 400;\">The effects of CYP3A4 or CYP2C8 inducers on the pharmacokinetics of apalutamide ha<\/span><span style=\"font-weight: 400;\">v<\/span><span style=\"font-weight: 400;\">e not been evaluated in vivo. Based on the drug-drug interaction study results with strong CYP3A4 inhibitor or <\/span><span style=\"font-weight: 400;\">strong CYP2C8 inhibitor, C<\/span><i><span style=\"font-weight: 400;\">Y<\/span><\/i><span style=\"font-weight: 400;\">P3A4 or C<\/span><i><span style=\"font-weight: 400;\">Y<\/span><\/i><span style=\"font-weight: 400;\">P2C8 inducers <\/span><span style=\"font-weight: 400;\">a<\/span><span style=\"font-weight: 400;\">re not <\/span>expe<span style=\"font-weight: 400;\">cted to have clinically relevant effects on the pharmacokinetics <\/span><span style=\"font-weight: 400;\">of apalutarnide and the active moieties therefore no dose adjustment is necessary when Apalutamide is co-administered with inducers of <\/span><span style=\"font-weight: 400;\">CYP3A4 or CYP2C8.\u00a0<\/span><\/p>\n<h3><b>Effect of Apalutamide on Other Drugs<\/b><\/h3>\n<p><b> <\/b><b>C<\/b><b>Y<\/b><b>P<\/b><b>3A4, CYP2C9, CYP2C19 and UGT Substrates: <\/b><span style=\"font-weight: 400;\">Apalutamide is a strong inducer of CYP3A4 and CYP2C19, and a <\/span>weak <span style=\"font-weight: 400;\">i<\/span><span style=\"font-weight: 400;\">n<\/span><span style=\"font-weight: 400;\">ducer of CYP2C9 in humans. Concomitan<\/span><span style=\"font-weight: 400;\">t us<\/span><span style=\"font-weight: 400;\">e of <\/span><span style=\"font-weight: 400;\">Apalutamide w<\/span><span style=\"font-weight: 400;\">i<\/span><span style=\"font-weight: 400;\">th medications that are primarily metabolized by <\/span><span style=\"font-weight: 400;\">CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these <\/span><span style=\"font-weight: 400;\">medications. Substitution for these medications is recommended when <\/span><span style=\"font-weight: 400;\">p<\/span><span style=\"font-weight: 400;\">ossible or evaluate for loss of activity if medication is continued. Concomitant administration of Apalutarnide with medications that are substrates of UDP-glucuronosyl transferase (UGT) can result in <\/span>decreased e<span style=\"font-weight: 400;\">xposure. Use caution if substrates of UGT must be co-administered with Apalutamide and evaluate for loss of activity.\u00a0<\/span><\/p>\n<p><b>P-gp, BCRP or OATP1B1 Substrates: <\/b><span style=\"font-weight: 400;\">Apalutamide <\/span><span style=\"font-weight: 400;\">wa<\/span><span style=\"font-weight: 400;\">s shown to <\/span><span style=\"font-weight: 400;\">b<\/span><span style=\"font-weight: 400;\">e a <\/span><span style=\"font-weight: 400;\">w<\/span><span style=\"font-weight: 400;\">eak inducer of P-glycoprotein <\/span><span style=\"font-weight: 400;\">(<\/span><span style=\"font-weight: 400;\">P-gp), breast cancer resistance protein (BCRP), and organic anion <\/span><span style=\"font-weight: 400;\">transporting polypeptide 1B1 <\/span><i><span style=\"font-weight: 400;\">(<\/span><\/i><span style=\"font-weight: 400;\">OATP1B1) clinically. At steady-state, Apalutamide reduced the plasma exposure to fexofenadine (a P-gp <\/span><span style=\"font-weight: 400;\">substrate) and rosuvastatin (a BCRP<\/span><i><span style=\"font-weight: 400;\">\/<\/span><\/i><span style=\"font-weight: 400;\">OATP1B1 substrate).\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Concomitant use of Apalutamide with medications that are substr<\/span><b>ates <\/b><span style=\"font-weight: 400;\">of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP or OATP1B1 <\/span><span style=\"font-weight: 400;\">must be co-administered with Apalutamide and evaluate for loss of <\/span><span style=\"font-weight: 400;\">activity if medication is continued.\u00a0<\/span><\/p>\n<h4><b>USE IN SPECIFIC POPULATION:<\/b><\/h4>\n<p><b>Pregnancy: <\/b><span style=\"font-weight: 400;\">Apalutamide is contraindicated in women who are or may become pregnant. Based on its mechanism of action, Apalutamide may caus<\/span><span style=\"font-weight: 400;\">e <\/span><span style=\"font-weight: 400;\">fatal harm when administered during pregnancy. T<\/span><span style=\"font-weight: 400;\">h<\/span><span style=\"font-weight: 400;\">ere are no data available from the use of Apalutamide in pregnant women. Animal <\/span><span style=\"font-weight: 400;\">reproductive studies have not been conducted with Apalutamide.\u00a0<\/span><\/p>\n<p><b>Fertility: <\/b><span style=\"font-weight: 400;\">B<\/span><span style=\"font-weight: 400;\">ased on animal studies, Apalutamide may decrease fertility in males of reproductive potential.\u00a0<\/span><\/p>\n<p><b>Breast-<\/b><b>f<\/b><b>eeding: <\/b><span style=\"font-weight: 400;\">It is unknown whether apalutamide<\/span><i><span style=\"font-weight: 400;\">\/<\/span><\/i><span style=\"font-weight: 400;\">metabolites a<\/span><span style=\"font-weight: 400;\">re <\/span><span style=\"font-weight: 400;\">excreted <\/span><span style=\"font-weight: 400;\">i<\/span><span style=\"font-weight: 400;\">n <\/span><span style=\"font-weight: 400;\">human milk. <\/span><span style=\"font-weight: 400;\">A r<\/span><span style=\"font-weight: 400;\">isk to <\/span><span style=\"font-weight: 400;\">th<\/span><span style=\"font-weight: 400;\">e suckling child cannot be excluded. <\/span><span style=\"font-weight: 400;\">Apalutamide should not be used during breast-feeding.\u00a0<\/span><\/p>\n<h4><b>Females and Males of Reproductive Potential\u00a0<\/b><\/h4>\n<p><b>Contraception in males and females: <\/b><span style=\"font-weight: 400;\">It is not known whether apalutamide or its metabolites are present in <\/span><span style=\"font-weight: 400;\">semen. Apalutamide may be harmful to a developing foetus. For <\/span><span style=\"font-weight: 400;\">patients having sex with female partners of reproductive potential, <\/span><span style=\"font-weight: 400;\">a <\/span><span style=\"font-weight: 400;\">condom should <\/span><span style=\"font-weight: 400;\">be <\/span><span style=\"font-weight: 400;\">u<\/span><span style=\"font-weight: 400;\">sed a<\/span><span style=\"font-weight: 400;\">long <\/span><span style=\"font-weight: 400;\">w<\/span><span style=\"font-weight: 400;\">ith another highly <\/span><span style=\"font-weight: 400;\">ef<\/span><span style=\"font-weight: 400;\">fective <\/span><span style=\"font-weight: 400;\">contraceptive method during treatment and for 3 months after the last dose of Apalutamide.<\/span><\/p>\n<h4><b>OVERDOSE <\/b><\/h4>\n<p><span style=\"font-weight: 400;\">There is no known specific antidote for apalutamide overdose. In the <\/span><span style=\"font-weight: 400;\">event of an overdose, stop Apalutamide, undertake general supportive <\/span><span style=\"font-weight: 400;\">measures until clinical toxicity has been diminished or resolved.\u00a0<\/span><\/p>\n<h5><b>PHARMACEUTICAL INFORMATION<\/b><\/h5>\n<p><b> <\/b><b>STORAGE:\u00a0 <\/b><span style=\"font-weight: 400;\">Store below 30\u00b0C. Keep PROSTAXEN out of the sight and reach of <\/span><span style=\"font-weight: 400;\">children. Protect from moisture and light.\u00a0<\/span><\/p>\n<h4><b>How Supplied <\/b><\/h4>\n<p><b>PR<\/b><b>OSTAXEN Tablet: <\/b>E<span style=\"font-weight: 400;\">ach HDPE container of PROSTAXEN contains 30 film-coated tablets (each tablet contains 60 mg Apalutamide) a <\/span><span style=\"font-weight: 400;\">silica gel desiccant and polyester coil with a child-resistant closure. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Product Feature:<\/strong><\/p>\n<table style=\"height: 126px;\" width=\"356\">\n<tbody>\n<tr>\n<td>Manufacturer<\/td>\n<td>: Everest Pharma Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Indication<\/td>\n<td>: Prostate cancer<\/td>\n<\/tr>\n<tr>\n<td>Strength<\/td>\n<td>: 60 mg<\/td>\n<\/tr>\n<tr>\n<td>Quantity<\/td>\n<td>: 30 Tablets<\/td>\n<\/tr>\n<tr>\n<td>Storage<\/td>\n<td>: Below 30\u00b0C<\/td>\n<\/tr>\n<tr>\n<td>Registrations<\/td>\n<td>: Export Only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"featured_media":3033,"comment_status":"open","ping_status":"closed","template":"","meta":[],"mc_generic":[320],"brands":[404],"product_cat":[108,43,441],"product_tag":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/product\/2308"}],"collection":[{"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/comments?post=2308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/media\/3033"}],"wp:attachment":[{"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/media?parent=2308"}],"wp:term":[{"taxonomy":"mc_generic","embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/mc_generic?post=2308"},{"taxonomy":"brands","embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/brands?post=2308"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/product_cat?post=2308"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/emergencydrug.com\/ko-kr\/wp-json\/wp\/v2\/product_tag?post=2308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}